- Home
- Results news
- Triochem Products
- Q2 FY27 results
Triochem Products Q2 FY27 results: net profit ₹0.08 crore vs ₹0.19 crore loss
Triochem Products Ltd reported standalone revenue of ₹0 crore, other income of ₹0.17 crore and a net profit of ₹0.08 crore for Q2 FY27. Basic EPS was ₹3.43, compared with a loss of ₹7.86 in Q2 FY26, while total expenses fell 86.4% to ₹0.06 crore.
Key points
- Q2 FY27 total income was ₹0.17 crore, down 43.3% from ₹0.30 crore in Q2 FY26.
- Total expenses fell 86.4% to ₹0.06 crore from ₹0.44 crore in Q2 FY26.
- The company reported a net profit of ₹0.08 crore in Q2 FY27 against a net loss of ₹0.19 crore in Q2 FY26.
- Basic EPS was ₹3.43 in Q2 FY27, compared with a loss of ₹7.86 in Q2 FY26.
- H1 FY27 total income was ₹0.33 crore, while profit before tax was ₹0.23 crore and net profit was ₹0.18 crore.
How did Triochem Products perform in Q2 FY27?
Triochem Products reported standalone revenue of ₹0 crore for Q2 FY27, unchanged from Q2 FY26 and Q1 FY27. Other income was ₹0.17 crore, down 43.3% from ₹0.30 crore a year earlier but unchanged from the previous quarter. Total expenses were ₹0.06 crore, down 86.4% from ₹0.44 crore in Q2 FY26 and up 50.0% from ₹0.04 crore in Q1 FY27.
The company reported a net profit of ₹0.08 crore in Q2 FY27 against a net loss of ₹0.19 crore in Q2 FY26. Profit before tax was ₹0.11 crore, compared with a loss of ₹0.15 crore a year earlier. Basic EPS was ₹3.43, against a loss of ₹7.86 in Q2 FY26 and ₹3.87 in Q1 FY27. No consolidated figures were given.
EBITDA was reported at ₹0.06 crore in Q2 FY27, compared with ₹0.42 crore in Q2 FY26 and ₹0.04 crore in Q1 FY27. An EBITDA margin was not reported. The results were standalone, and the board approved the unaudited results for the quarter and half year ended 30 September 2026 on 4 November 2026.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0 | 0 | 0 | ||
| Other income | 0.17 | 0.17 | 0.30 | −43.3% | +0.0% |
| Total expenses | 0.06 | 0.04 | 0.44 | −86.4% | +50.0% |
| EBITDA | −0.06 | −0.04 | −0.42 | ||
| Profit before tax | 0.11 | 0.12 | −0.15 | turned to profit | −8.3% |
| Tax | 0.03 | 0.03 | 0.05 | −40.0% | +0.0% |
| Net profit | 0.08 | 0.09 | −0.19 | turned to profit | −11.1% |
| EPS (₹) | 3.43 | 3.87 | −7.86 | turned to profit | −11.4% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Triochem Products' costs and profit?
Against Q2 FY26, total expenses fell by ₹0.38 crore, or 86.4%, to ₹0.06 crore. Employee cost declined by ₹0.13 crore, or 92.9%, to ₹0.01 crore, while other expenses fell by ₹0.24 crore, or 82.8%, to ₹0.05 crore. Depreciation fell by ₹0.02 crore to ₹0 crore; cost of materials and finance costs were unchanged at ₹0 crore.
Other income declined by ₹0.13 crore, or 43.3%, to ₹0.17 crore in Q2 FY27. Despite the lower other income, profit before tax improved by ₹0.26 crore to ₹0.11 crore, while net profit improved by ₹0.27 crore to ₹0.08 crore. Tax expense fell by ₹0.02 crore, or 40.0%, to ₹0.03 crore. There was no exceptional item.
Against Q1 FY27, total expenses increased by ₹0.02 crore, or 50.0%, to ₹0.06 crore because other expenses increased by ₹0.02 crore, or 66.7%, to ₹0.05 crore. Employee cost, finance costs, depreciation, other income and tax were unchanged. Profit before tax and net profit each declined by ₹0.01 crore, and basic EPS fell by ₹0.44 to ₹3.43.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 0 | 0 | 0 | |
| Employee cost | 0.01 | 0.14 | −0.13 | −92.9% |
| Finance costs | 0 | 0 | 0 | |
| Depreciation | 0 | 0.02 | −0.02 | |
| Other expenses | 0.05 | 0.29 | −0.24 | −82.8% |
| Total expenses | 0.06 | 0.44 | −0.38 | −86.4% |
| Other income | 0.17 | 0.30 | −0.13 | −43.3% |
| Tax | 0.03 | 0.05 | −0.02 | −40.0% |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For the first half of FY27, total income was ₹0.33 crore, down ₹0.19 crore or 36.5% from ₹0.52 crore in H1 FY26. Revenue was unchanged at ₹0 crore. Profit before tax moved from a loss of ₹0.30 crore to a profit of ₹0.23 crore, an improvement of ₹0.53 crore, while net profit moved from a loss of ₹0.22 crore to a profit of ₹0.18 crore.
Basic EPS in H1 FY27 was ₹7.30, compared with a loss of ₹9.11 in H1 FY26, an improvement of ₹16.41. The standalone results were approved by the board and reviewed by the statutory auditors, whose review report was included with the filing.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 0 | 0 | |
| Profit before tax | 0.23 | −0.30 | turned to profit |
| Net profit | 0.18 | −0.22 | turned to profit |
| EPS (₹) | 7.30 | −9.11 |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹21.91 crore, compared with ₹20.88 crore at 31 March 2026. Total equity was ₹21.37 crore against ₹20.65 crore at the previous balance sheet date. Cash was ₹11.70 crore versus ₹11.73 crore, while borrowings were ₹0 crore at both dates.
For H1 FY27, operating cash flow was ₹0.02 crore, compared with a negative ₹0.29 crore in H1 FY26. Investing cash flow was a negative ₹0.04 crore, compared with a negative ₹0.10 crore a year earlier. Financing cash flow and capital expenditure were ₹0 crore in both periods.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 21.91 | 20.88 |
| Total equity | 21.37 | 20.65 |
| Borrowings | 0 | 0 |
| Cash and equivalents | 11.70 | 11.73 |
| Inventories | 0 | 0 |
| Trade receivables | 0 | 0 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 0.02 | −0.29 |
| Cash from investing | −0.04 | −0.10 |
| Cash from financing | 0 | 0 |
| Capital expenditure | 0 | 0 |
Source: Company's results filing (XBRL).
How has Triochem Products done over the last 8 quarters?
The quarterly profit series shows a loss of ₹0.45 crore in Q4 FY25, followed by losses of ₹0.03 crore in Q1 FY26, ₹0.19 crore in Q2 FY26 and ₹0.13 crore in Q3 FY26. Profit then rose to ₹8.33 crore in Q4 FY26 before easing to ₹0.09 crore in Q1 FY27 and ₹0.08 crore in Q2 FY27.
Revenue was ₹0 crore in each of the last eight quarters, and no EBITDA margin was reported for those quarters. The latest direction was therefore a lower net profit than Q1 FY27, with profit remaining well below the Q4 FY26 peak. A streak was not provided.
How did other Pharmaceuticals companies do?
A total of 65 Pharmaceuticals companies were compared for the quarter. Their median revenue growth was 18.9%, while Triochem Products reported revenue of ₹0 crore in both Q2 FY27 and Q2 FY26. The filing did not state how many peers grew more slowly or faster than the company.
Of the 59 peers for which profit was compared, 42 reported higher profit. Triochem Products reported a net profit of ₹0.08 crore, compared with a net loss of ₹0.19 crore in Q2 FY26, while its basic EPS was ₹3.43 against a loss of ₹7.86.
| Triochem Products revenue growth (YoY) | not comparable |
|---|---|
| Median of 65 other Pharmaceuticals companies | +18.9% |
| Companies whose net profit rose | 42 of 59 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Triochem Products' revenue in Q2 FY27?
Revenue from operations was ₹0 crore, against ₹0 crore in Q2 FY26 (standalone).
Did Triochem Products make a profit in Q2 FY27?
Yes. Net profit was ₹0.08 crore, against a net loss of ₹0.19 crore in Q2 FY26.
What was Triochem Products' EPS in Q2 FY27?
Basic earnings per share were ₹3.43, against a loss of ₹7.86 in Q2 FY26.
When did Triochem Products announce its Q2 FY27 results?
On 4 November 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Board Of Director Meeting Of Triochem Products Limited Will Meet On Wednesday, 4Th November 2026 At 03.00 P.M. At The Registered Office Of Company (BSE, 24 October 2026) · PDF
- Submission Of Unaudited Standalone Financial Results For The Quarter And Half Year Ended 30Th September 2026 (BSE, 4 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.